导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.32% | 1407/4773 |
| 近一周 | 0.77% | 68/5462 |
| 近一月 | 5.75% | 34/5421 |
| 近一季 | 5.88% | 250/5209 |
| 近半年 | 6.86% | 652/4920 |
| 近一年 | 4.12% | 1791/4366 |
| 近两年 | 40.67% | 1863/2954 |
| 近三年 | 49.59% | 545/2253 |
| 成立以来 | 77.75% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.69% 2864/4961 |
-7.99% 3822/5312 |
- - |
- - |
| 2025 | 10.50% 2807/4813 |
2.61% 1308/3635 |
11.55% 164/4076 |
-8.49% 4042/4524 |
5.49% 436/4813 |
| 2024 | 39.28% 26/3463 |
10.09% 75/2808 |
6.88% 115/3014 |
12.59% 2314/3129 |
5.13% 634/3463 |
| 2023 | -2.43% 580/2656 |
-2.47% 1992/2280 |
2.16% 160/2385 |
4.75% 130/2515 |
-6.51% 1806/2655 |
| 2022 | -4.29% 88/2207 |
2.23% 67/1919 |
-1.36% 1714/2016 |
-8.12% 171/2113 |
3.31% 725/2208 |
| 2021 | 1.22% 684/1822 |
10.56% 32/1255 |
-1.45% 1167/1330 |
-6.74% 984/1466 |
-0.39% 1231/1822 |
| 2020 | 4.74% 890/1250 |
-12.76% 900/1028 |
3.01% 953/1067 |
5.72% 897/1164 |
10.25% 606/1184 |
| 2019 | 32.33% 449/1092 |
15.88% 680/739 |
2.79% 67/788 |
2.95% 277/850 |
7.91% 382/918 |
| 2018 | -10.09% 69/834 |
- - |
-9.95% 292/631 |
11.64% 2/660 |
-9.04% 119/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 南方中证银行ETF发起联接A VS. 长安沪深300非周期A(740101) |